Medical insurance reimbursement conditions for giritinib

Gilteritinib is a drug used to treat certain types of leukemia. It belongs to a class of drugs called tyrosine kinase inhibitors, which help control the proliferation and spread of leukemia cells by inhibiting abnormally active tyrosine kinases in cells.

Although giritinib has entered the Chinese market, unfortunately, it has not yet been included in the medical insurance system, so the domestic price remains high, as high as more than 20,000 yuan. For detailed prices, please consult your local hospital or pharmacy.

In comparison, the prices of foreign generic drugs are more affordable, especially those produced in Laos. The price is about two to three thousand yuan, which is far lower than the domestic market price. It is worth mentioning that the main pharmaceutical ingredients of these generic drugs are very close to those of our original drugs.

Giritinib is primarily indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) and FLT3-ITD (internal dinucleotide insertion) or FLT3-TKD (point mutation within the tyrosine kinase domain) mutation AML. FLT3mutations are common in AML patients and lead to abnormal cell proliferation and progression of leukemia.

Giritinib works by blockingFLT3kinase activity. FLT3kinase plays an important role in regulating cell proliferation and survival in normal cells, but in leukemia cells, especially those cells carrying FLT3 mutations, its activity is abnormally enhanced. The function of giritinib is to selectively inhibit the activity of FLT3 kinase, thereby preventing the proliferation and survival of leukemia cells, helping to control the disease and prolong the survival time of patients.

This medication is usually available in an oral dosage form that patients can take daily as directed by their doctor. During the treatment process, the doctor will adjust the dosage according to the patient's specific condition and conduct regular monitoring to evaluate the efficacy and possible side effects.